What's the Problem? Cultural Capability and Learning from Historical Performance

Contains the cis-eQTLs with P value < 5 % for T-cells obtained from early undifferentiated arthritis patients. (TXT 1162 kb

Consolidation of Roadmap epigenomics 18-state chromatin states into four exclusive annotations.

Consolidation of Roadmap epigenomics 18-state chromatin states into four exclusive annotations.</p

Enrichment of immune-enriched lncRNA amongst RA susceptibility variants after conditioning on chromatin state data.

The influence of immune-relevant enhancers (red circle) was fixed in a probabilistic model of RA susceptibility to determine whether the subtle enrichment of FANTOM CAT immune-enriched lncRNA or mRNA adds any additional predictive information and is therefore independently enriched. Genic (black circle) and exonic (grey diamond) annotations were both tested. As may be expected given the magnitude of enrichments observed, after accounting for the effect of immune-enriched FANTOM CAT annotations, the residual enrichment of immune-relevant enhancers is not dramatically reduced (S2 Fig). </p

Enrichment of lncRNA annotations amongst RA susceptibility variants.

Estimates for the enrichment of genic (black circle) and exonic (grey diamond) annotations from a variety of lncRNA containing databases, including 95% confidence intervals (A). Separate estimates are included for annotations identified as exhibiting enriched expression in immune-relevant cells (B).</p

Distribution of immune-enriched lncRNA and mRNA expression levels in primary T-helper cells.

Staggered bars are used to illustrate the proportion of transcripts whose expression falls in bins of 25 million transcripts, or counts, in Roadmap Epigenomics RNA-seq data (A) and FANTOM CAT CAGE data (B), respectively.</p

Enrichment of chromatin state groups amongst RA susceptibility variants for 98 cell types.

Estimates for enrichment of combined chromatin state groupings are illustrated for all 98 cell types annotated within the Roadmap Epigenomics 18-state model. Cell-types are ordered and coloured according to the clustering established by the Roadmap Epigenomics project, with immune-relevant cell types coloured green. Estimates and confidence intervals are clipped at axis limits, where applicable.</p

Visual interpretation of analysis pipeline.

GWAS summary stats were used to inform a probabilistic model of RA susceptibility. Various features were taken from publically available data and their ability to improve this model was tested, features that improve the model can be thought of as enriched amongst RA susceptibility variants.</p

Additional file 1: Table S1. of Optimisation of methods for bacterial skin microbiome investigation: primer selection and comparison of the 454 versus MiSeq platform

Comparison of the relative abundance (%) of bacterial mock community at the classification level of family. Table S2a. Comparison of the relative abundance (%) of bacterial taxa from healthy human skin samples at the phylum level (data available for two samples for the V3-V4 primer pair and one sample for V1-V3 primer pair). Table S2b. Comparison of the relative abundance (%) of bacterial taxa from healthy human skin samples at the genus level (data available for two samples for the V3-V4 primer pair and one sample for V1-V3 primer pair). Skin sampling: Requirements for skin sampling and skin preparation instructions provided to healthy volunteers. (DOCX 40 kb

Type II diabetes mellitus and cardiovascular markers in humans: a prospective study in hellenic homogeneous population

Approximately 200 million people, worldwide, are currently having Type 2 diabetes mellitus (T2DM), a prevalence that has been predicted to increase to 366 million by 2030. Atherosclerotic coronary heart disease (CHD) and other forms of cardiovascular disease (CYD) are the major cause of mortality in T2DM as well as a major contributor to morbidity and lifetime costs. A number of unfavorable conditions predisposing to CVD coexist with diabetic status including hyperglycaemia, dyslipidaemia, inflammation and coagulation, many of which may be closely associated with insulin resistance. In addition, mutations and polymorphisms in a number of genes have also been linked with monogenic and polygenic forms of T2DM. In this respect, the possible relationship between these disorders and a number of biochemical factors in a selection of different age groups of diabetic patients was studied. The purpose of the present work was the identification of biochemical parameters in plasma, which may serve as predisposition factors to CVD in T2DM patients of different age. The variability of hyperglycaemia, dyslipidaemia, and inflammation with age progression were studied. Four different diabetic groups allocated based on the subjects age (Group A:15-25 years old; Group 13:26-40 years old; Group C:40-60 years old; Group D:60-80 years old) and consisting of ten patients each, in parallel with ten matched for age, sex and ethnic origin healthy controls, were screened for glucose, insulin, lipid profile (total cholesterol, triglycerides, LDL and HDL) and inflammatory mediators (Homocysteine, CRP, IL-6, TNF-a). Significant differences were observed between the expression of biochemical markers among different age groups. Hyperglycaemia showed no variability with age whereas dyslipidaemia correlated positively with age progression, as well as obesity, low physical activity and family history of heart disease or diabetes. Marked inflammation was prominent only in Groups C and D. The present study indicates that different biochemical parameters may be used for assessment of CVD risk in T2DM patients of variable age

Overview of MS 6q23 interactions.

<p>Tracks are labelled as follows: A–LD regions targeted in ‘region’ Capture Hi-C; B–Gene regions targeted in ‘promoter’ Capture Hi-C; C–RefSeq genes (packed for clarity); D–MS index SNPs; E–MS LD regions; F–Interactions observed in the GM12878 B-cell line and G–Interactions observed in the Jurkat T-cell line. Promoter and region Capture Hi-C experiments have been merged for clarity. The genomic region chr6:136,650,000–137,280,000 has been omitted for clarity. All co-ordinates are based on GRCh37. Generated using the WashU EpiGenome Browser (<a href="http://epigenomegateway.wustl.edu/browser/" target="_blank">http://epigenomegateway.wustl.edu/browser/</a>).</p